Oncolytics Biotech Valuation
| ONCY Stock | USD 0.92 0.03 3.16% |
Today, the company appears to be undervalued. Oncolytics Biotech holds a recent Real Value of $2.49 per share. The prevailing price of the company is $0.92. Our model determines the value of Oncolytics Biotech from analyzing the company fundamentals such as Return On Equity of -1.38, shares outstanding of 76.86 M, and Shares Owned By Institutions of 1.76 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oncolytics Biotech's valuation include:
Price Book 5.2788 | Enterprise Value 53.9 M | Enterprise Value Ebitda (1.79) |
Undervalued
Today
Please note that Oncolytics Biotech's price fluctuation is relatively risky at this time. Calculation of the real value of Oncolytics Biotech is based on 3 months time horizon. Increasing Oncolytics Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Oncolytics Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oncolytics Stock. However, Oncolytics Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.92 | Real 2.49 | Target 7.33 | Hype 0.92 | Naive 0.89 |
The intrinsic value of Oncolytics Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Oncolytics Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Oncolytics Biotech helps investors to forecast how Oncolytics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oncolytics Biotech more accurately as focusing exclusively on Oncolytics Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Oncolytics Biotech's intrinsic value based on its ongoing forecasts of Oncolytics Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Oncolytics Biotech's closest peers.
Oncolytics Biotech Cash |
|
Oncolytics Valuation Trend
Analysing the historical paterns of Oncolytics Biotech's enterprise value and its market capitalization is a good way to estimate and gauge the value of Oncolytics Biotech over time and is usually enough for investors to make rational market timing decisions.
Oncolytics Biotech Total Value Analysis
Oncolytics Biotech is now forecasted to have valuation of 53.9 M with market capitalization of 71.4 M, debt of 423 K, and cash on hands of 32.36 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Oncolytics Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
53.9 M | 71.4 M | 423 K | 32.36 M |
Oncolytics Biotech Asset Utilization
One of the ways to look at asset utilization of Oncolytics is to check how much profit was generated for every dollar of assets it reports. Oncolytics Biotech holds a negative application of assets of -0.71 pct., losing $0.007133 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Oncolytics Biotech shows how discouraging it operates for each dollar spent on its assets.Oncolytics Biotech Ownership Allocation
Oncolytics Biotech owns a total of 76.86 Million outstanding shares. Oncolytics Biotech holds 3.81 pct. of its outstanding shares held by insiders and 1.76 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Oncolytics Biotech Profitability Analysis
Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0.About Oncolytics Biotech Valuation
Our relative valuation model uses a comparative analysis of Oncolytics Biotech. We calculate exposure to Oncolytics Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oncolytics Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -403 K | -423.1 K | |
| Pretax Profit Margin | (6.74) | (7.08) | |
| Operating Profit Margin | (6.81) | (7.15) | |
| Net Loss | (6.75) | (7.08) |
Oncolytics Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 67.6 M |
Oncolytics Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Oncolytics Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Oncolytics we look at many different elements of the entity such as Oncolytics's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Oncolytics Biotech's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Oncolytics Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Oncolytics Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Oncolytics Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Oncolytics Biotech's worth.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.